| NASDAQ (usa) |
 |
6715.56 | -12.11 | -0.18% |
| FTSE 100 (london) |
|
7487.96 | -5.12 | -0.07% |
| DAX (german) |
 |
13465.51 | 235.94 | 1.78% |
| NIKKEI 225 (japan) |
|
22420.08 | 408.47 | 1.86% |
| Hang - Seng (hong kong) |
|
28594.06 | 348.52 | 1.23% |
| NIFTY - 50 (india) | ||||
| Straits Times (singapore) |
|
3391.61 | 17.53 | 0.52% |
| KOSPI (korea) |
|
2556.47 | 33.04 | 1.31% |
| All Ordinaries (australia) |
|
6005.30 | 28.90 | 0.48% |
| BOVESPA (brazil) |
|
74092.76 | -215.73 | -0.29% |
Sun Pharma Advanced Research Company Limited (NSE: SPARC)
SPARC Technical Analysis
5
| As on 25th Jan 2022 SPARC Share Price closed @ 320.95 and we RECOMMEND Strong Buy for LONG-TERM with Stoploss of 244.34 & Strong Buy for SHORT-TERM with Stoploss of 275.57 we also expect STOCK to react on Following IMPORTANT LEVELS. |
SPARC Share Price
| Open | 305.00 | Change | Price | % |
| High | 328.90 | 1 Day | 14.50 | 4.73 |
| Low | 303.05 | 1 Week | 6.45 | 2.05 |
| Close | 320.95 | 1 Month | 74.70 | 30.34 |
| Volume | 1158248 | 1 Year | 136.80 | 74.29 |
| 52 Week High 337.85 | 52 Week Low 141.00 | ||||
NSE INDIA Most Active Stocks
| IDEA | 11.30 | 3.20% |
| VISESHINFO | 1.55 | 3.33% |
| JPPOWER | 9.05 | 2.84% |
| SUZLON | 11.00 | -0.90% |
| ZOMATO | 100.45 | 9.96% |
| YESBANK | 13.60 | 1.12% |
| BANKBARODA | 98.50 | 6.37% |
| PNB | 39.40 | 3.68% |
| ALOKINDS | 29.70 | 2.77% |
| INVENTURE | 5.45 | -4.39% |
NSE INDIA Top Gainers Stocks
| SALONA | 327.00 | 20.00% |
| SHARDACROP | 525.35 | 20.00% |
| AMBICAAGAR | 34.05 | 18.85% |
| PRESSMN | 48.65 | 16.67% |
| CORALFINAC | 49.85 | 14.60% |
| TRITURBINE | 214.30 | 14.42% |
| OMAXE | 93.10 | 13.95% |
| ARMANFIN | 792.95 | 13.76% |
| ORBTEXP | 100.00 | 13.44% |
| BIL | 304.25 | 12.31% |
NSE INDIA Top Losers Stocks
| SPARC Daily Charts |
SPARC Intraday Charts |
Whats New @ Bazaartrend |
SPARC Free Analysis |
|
|
SPARC Important Levels Intraday
| RESISTANCE | 370.76 |
| RESISTANCE | 354.79 |
| RESISTANCE | 344.91 |
| RESISTANCE | 335.04 |
| SUPPORT | 306.86 |
| SUPPORT | 296.99 |
| SUPPORT | 287.11 |
| SUPPORT | 271.14 |
SPARC Target for Month January
| 4th UP TARGET | 388.45 |
| 3rd UP TARGET | 355.88 |
| 2nd UP TARGET | 335.75 |
| 1st UP TARGET | 315.62 |
| 1st DOWN TARGET | 258.18 |
| 2nd DOWN TARGET | 238.05 |
| 3rd DOWN TARGET | 217.92 |
| 4th DOWN TARGET | 185.35 |
SPARC Weekly Target
| 4th UP TARGET | 375.24 |
| 3rd UP TARGET | 358.21 |
| 2nd UP TARGET | 347.69 |
| 1st UP TARGET | 337.16 |
| 1st DOWN TARGET | 307.14 |
| 2nd DOWN TARGET | 296.61 |
| 3rd DOWN TARGET | 286.09 |
| 4th DOWN TARGET | 269.06 |
SPARC Target for Year 2022
| 4th UP TARGET | 616.42 |
| 3rd UP TARGET | 510.74 |
| 2nd UP TARGET | 445.42 |
| 1st UP TARGET | 380.1 |
| 1st DOWN TARGET | 193.71 |
| 2nd DOWN TARGET | 128.38 |
| 3rd DOWN TARGET | 63.06 |
| 4th DOWN TARGET | -42.62 |
Sun Pharma Advanced Research Company Limited ( NSE INDIA Symbol : SPARC )
Sector : Healthcare And Other Stocks in Same Sector
Sector : Healthcare And Other Stocks in Same Sector
SPARC Synopsis Technicals View
| 50 Day EMA |
Close is Above EMA 50 (Short Term) |
Bullish | |
| 100 Day EMA | Close is Above EMA 100 (Mid Term) | Bullish | |
| 200 Day EMA | Close is Above EMA 200 (Long Term) | Bullish | |
| MACD (12 26 9) | MACD Line is Less Then SIGNAL Line | Bearish | |
| RSI (14) | RSI is Below 30 | Over Sold | |
| MFI (14) | MFI is 45.67 | Sideways | |
| CCI (20) | CCI is Below -100 | Over Sold | |
| WILLIAM %R (14) | William %R is Below -80 | Over Sold | |
| ADX (14) | ADX is Above 20 & +DI is Below -DI | Down Trend | |
| PSAR | Stoploss For Long Buy | 144.76 | |
| 10 Day Avg Volume | Traded -47.32 % Less then 10 Day Average Volume | ||
SPARC Other Details
| Segment | EQ | |
| Market Capital | 74794024960.00 | |
| Sector | Healthcare | |
| Industry | Drug Manufacturers-Specialty & Generic | |
| Offical website | > | |
SPARC Address
 |
||
SPARC Latest News
SPARC Business Profile
Sun Pharma Advanced Research Company Limited, a biopharmaceutical company, engages in the research and development of pharmaceutical products in India and internationally. It develops new chemical and biological entities, and reformulated products with a therapeutic focus on oncology, neurodegeneration, ophthalmology, and dermatology. The company offers Elepsia, a formulation of levetiracetam that is an anti-epileptic agent to treat epilepsy disorder; and Xelpros, a latanoprost ophthalmic emulsion for the treatment of open-angle glaucoma or ocular hypertension. In addition, it is developing SDN-037, a formulation of difluprednate for the treatment of inflammation and pain associated with ocular surgery that is in phase 3 clinical trial; PDP-716 to treat glaucoma, which is in phase 3 clinical trial; phenobarbital sodium for the treatment of neonatal seizures; Vodobatinib (SCO-088) for the treatment of resistant chronic myelogenous leukemia that has completed a part A of the Phase 1 study; Vodobatinib (SCC-138), which is in phase 2 clinical trial to treat Parkinson's disease; SCD-044 for the treatment of psoriasis and atopic dermatitis that is in phase 2 clinical trial; and SCO-120 for the treatment of hormone receptor-positive, human epidermal receptor 2 negative, and metastatic breast cancer, which is in phase 1 clinical trial. Sun Pharma Advanced Research Company Limited has a collaboration agreement with Bioprojet SCR to develop an S1P receptor 1 agonist for autoimmune disorders; and HitGen Ltd. to identify small molecule leads for targets of interest. The company was incorporated in 2006 and is based in Mumbai, India. Sun Pharma Advanced Research Company Limited is a subsidiary of Shanghvi Finance Private Limited Address: 17-B, Mahal Industrial Estate, Mumbai, India, 400093
© 2005-2021 BazaarTrend.com All rights reserved.
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service